NCT05279027View on ClinicalTrials.gov

Zr89 + PET Companion Trial

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

May 6, 2025

Study Completion Date

May 6, 2025

Conditions
Melanoma (Skin)
Interventions
DRUG

Zirconium Zr 89 Crefmirlimab Berdoxa

Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation

Trial Locations (1)

19104

Perleman Center for Advanced Medicine, Philadelphia

Sponsors

Collaborators (1)

ImaginAb, Inc.
All Listed Sponsors
collaborator

ImaginAb, Inc.

INDUSTRY

lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT05279027 - Zr89 + PET Companion Trial | Biotech Hunter | Biotech Hunter